HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Capital Markets

Shanghai Ark Biopharmaceutical / Equity Capital Markets

<p>In the era of excessive competition of anti-tumor drugs, many enterprises began to make layout in other fields such as ophthalmologic drugs, respiratory drugs, dermatologic drugs, antiviral drugs and so on. On June 29<sup>th</sup>, 2021, <a href="https://www.smartkarma.com/entities/shanghai-ark-biopharmaceutical-co-ltd" target="_blank" data-smartkarma-citation="entities:33766:1" rel="noopener">Shanghai Ark Biopharmaceutical (SAB HK)</a> submitted its prospectus to the HKEX and officially started its IPO process. Ark is an innovative biopharmaceutical company focused on the discovery and development of novel therapeutics addressing unmet medical needs in respiratory and lung diseases. This insight mainly analyzed the important product candidates in the pipeline and related concerns.</p>

In the era of excessive competition of anti-tumor drugs, many enterprises began to make layout in other fields such as ophthalmologic drugs, respiratory drugs, dermatologic drugs, antiviral drugs and so on. On June 29th, 2021, Shanghai Ark Biopharmaceutical (SAB HK) submitted its prospectus to the HKEX and officially started its IPO process. Ark is an innovative biopharmaceutical company focused on the discovery and development of novel therapeutics addressing unmet medical needs in respiratory and lung diseases. This insight mainly analyzed the important product candidates in the pipeline and related concerns.

Pre-IPO Shanghai Ark Biopharmaceutical - Insights on Pipeline and Related Concerns

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Pre-IPO Shanghai Ark Biopharmaceutical - Insights on Pipeline and Related Concerns

The article mainly analyzed Ark Biopharmaceutical in terms of the important product candidates AK0529 (ziresovir) and AK3280 that entered the...

Xinyao (Criss) Wang